4-(2-Methyl-1-(4-methylpiperazin-1-yl)-1-oxopropan-2-yl)-N-(6-(pyridin-4-yl)imidazo[1,2-a]pyridin-2-yl)benzamide, 4-[1,1-Dimethyl-2-(4-methyl-1-piperazinyl)-2-oxoethyl]-N-[6-(4-pyridinyl)imidazo[1,2-a]pyridin-2-yl]benzamide, T3
T3-CLK (T3) is a cell permeable, highly potent and selective cell-base stable inhibitor of CDC-like kinase (CLK) that exhibits dose-dependent alternative splicing effects in HCT116 colorectal cancer cells. T3-CLK increases conjoined gene (CG) transcription.
cell permeable, highly potent and selective cell-base stable inhibitor of CDC-like kinase (CLK)
Potent, selective and broadly characterized small molecule modulators of protein function (chemical probes) are powerful research reagents. The pharmaceutical industry has generated many high-quality chemical probes and several of these have been made available to academia. However, probe-associated data and
CDC-like kinase phosphorylation of serine/arginine-rich proteins is central to RNA splicing reactions. Yet, the genomic network of CDC-like kinase-dependent RNA processing events remains poorly defined. Here, we explore the connectivity of genomic CDC-like kinase splicing functions by applying graduated, short-exposure
